- MeSH
- Humans MeSH
- Health Care Costs MeSH
- Primary Prevention * statistics & numerical data MeSH
- Diagnostic Screening Programs statistics & numerical data MeSH
- Insurance, Health MeSH
- Check Tag
- Humans MeSH
- Publication type
- Newspaper Article MeSH
- Geographicals
- Czech Republic MeSH
- MeSH
- Health Services Accessibility MeSH
- Cardiology organization & administration statistics & numerical data MeSH
- Cardiovascular Diseases * prevention & control MeSH
- Humans MeSH
- General Practice organization & administration MeSH
- Primary Prevention * organization & administration statistics & numerical data MeSH
- Check Tag
- Humans MeSH
- Publication type
- Newspaper Article MeSH
- MeSH
- Humans MeSH
- Mammography statistics & numerical data MeSH
- Uterine Cervical Neoplasms diagnosis MeSH
- Colonic Neoplasms diagnosis MeSH
- Mass Screening statistics & numerical data MeSH
- Primary Prevention * statistics & numerical data MeSH
- Preventive Health Services statistics & numerical data MeSH
- Check Tag
- Humans MeSH
- Geographicals
- Czech Republic MeSH
- MeSH
- Aspirin * history pharmacology therapeutic use MeSH
- Stroke mortality prevention & control MeSH
- Myocardial Infarction mortality prevention & control MeSH
- Platelet Aggregation Inhibitors pharmacology therapeutic use MeSH
- Cardiovascular Diseases mortality prevention & control MeSH
- Clinical Trials as Topic MeSH
- Hemorrhage chemically induced MeSH
- Humans MeSH
- Primary Prevention methods statistics & numerical data MeSH
- Heart Disease Risk Factors * MeSH
- Check Tag
- Humans MeSH
- MeSH
- Substance Abuse Treatment Centers statistics & numerical data MeSH
- Community Integration statistics & numerical data MeSH
- Smoking legislation & jurisprudence MeSH
- Designer Drugs MeSH
- Drug Trafficking * statistics & numerical data legislation & jurisprudence MeSH
- Substance Abuse Detection statistics & numerical data legislation & jurisprudence MeSH
- Opiate Substitution Treatment statistics & numerical data MeSH
- Substance-Related Disorders * prevention & control therapy MeSH
- Primary Prevention methods statistics & numerical data MeSH
- National Health Programs legislation & jurisprudence MeSH
- Illicit Drugs legislation & jurisprudence MeSH
- Geographicals
- Czech Republic MeSH
- MeSH
- Adult MeSH
- Contraceptives, Oral, Hormonal * adverse effects therapeutic use MeSH
- Cigarette Smoking epidemiology adverse effects MeSH
- Middle Aged MeSH
- Humans MeSH
- Adolescent MeSH
- Drug-Related Side Effects and Adverse Reactions epidemiology etiology MeSH
- Pilot Projects MeSH
- Primary Prevention statistics & numerical data trends MeSH
- Surveys and Questionnaires MeSH
- Activated Protein C Resistance diagnosis epidemiology complications MeSH
- Risk Factors MeSH
- Venous Thromboembolism epidemiology etiology MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Adolescent MeSH
- Female MeSH
BACKGROUND: The subcutaneous implantable defibrillator (S-ICD) provides an alternative to the transvenous ICD for the prevention of sudden cardiac death, but has not been well studied in the most commonly treated transvenous ICD patient population, namely, primary prevention (PP) patients with left ventricular dysfunction. OBJECTIVE: The analyses in the present study were designed to compare clinical outcomes for PP patients with and without a reduced ejection fraction (EF) and secondary prevention (SP) patients implanted with the S-ICD. METHODS: All patients 18 years and older from the S-ICD IDE study and the EFFORTLESS Registry with available data as of November 18, 2013, were included (n = 856; mean follow-up duration 644 days). Outcomes were evaluated in 2 analyses: (1) comparing all PP patients (n = 603, 70.4%) with all SP patients (n = 253, 29.6%) and (2) comparing all PP patients with an EF ≤35% (n = 379) with those with an EF >35% (n = 149, 17.4%). RESULTS: No differences were observed in mortality, complications, inappropriate therapy, or ability to convert ventricular tachyarrhythmias between SP and PP patients. However, SP patients had a higher incidence of appropriate therapy than did PP patients (11.9% vs 5.0%; P = .0004). In the PP subanalysis, the cohort with an EF ≤35% had significantly older patients with more comorbidities and higher mortality (3.0% annually vs 0.0%). Despite these differences, device-related complications, conversion efficacy, and incidence of inappropriate shock therapies were not significantly different between PP subgroups. CONCLUSION: The S-ICD performs well in protecting patients with either PP or SP implant indications from sudden cardiac death. Within PP patients, device performance was independent of EF.
- MeSH
- Defibrillators, Implantable * MeSH
- Adult MeSH
- Ventricular Dysfunction, Left * diagnosis physiopathology MeSH
- Electric Countershock * adverse effects instrumentation methods MeSH
- Kaplan-Meier Estimate MeSH
- Tachycardia, Ventricular * mortality therapy MeSH
- Middle Aged MeSH
- Humans MeSH
- Death, Sudden, Cardiac prevention & control MeSH
- Primary Prevention methods statistics & numerical data MeSH
- Prosthesis Fitting MeSH
- Registries MeSH
- Secondary Prevention methods statistics & numerical data MeSH
- Aged MeSH
- Stroke Volume MeSH
- Outcome and Process Assessment, Health Care MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Comparative Study MeSH
- MeSH
- Humans MeSH
- Melanoma * prevention & control MeSH
- Skin Neoplasms prevention & control MeSH
- Primary Prevention * economics statistics & numerical data MeSH
- Check Tag
- Humans MeSH
- Publication type
- Newspaper Article MeSH
- Keywords
- preventivní prohlídky, programy primární prevence,
- MeSH
- Program Evaluation MeSH
- Humans MeSH
- Mass Screening MeSH
- Health Promotion MeSH
- Primary Prevention * methods organization & administration statistics & numerical data MeSH
- Primary Health Care methods MeSH
- Preventive Health Services MeSH
- Check Tag
- Humans MeSH
